Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel and Ketamine in Treatment Resistant Depression
NCT03367533Phase 1Completed
- Sponsor
- Yale University
- Start
- Nov 2018
- Primary completion
- Jul 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of perampanel in major depressive disorder (MDD), bipolar disorder (BD) and post-traumatic stress disorder (PTSD), sponsored by Yale University. Primary endpoint: Prefrontal functional connectivity. Started Nov 2018; status: completed.
02
Drugs
perampanel
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03367533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367533.